Approval · Notice of Compliance 28083 · 2022
MYLAN-DIVALPROEX: Notice of Compliance 28083
Issued May 4, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28083
- Date
- May 4, 2022
- Company
- Mylan Pharmaceuticals UlcEtobicoke, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Convert the Product Monograph to the 2020 Master Template and Update to the Labels.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MYLAN-DIVALPROEX | Not yet assigned | — |
Medicinal ingredients
- VALPROIC ACID 125 MG per TAB
- VALPROIC ACID 250 MG per TAB
- VALPROIC ACID 500 MG per TAB